This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Herve Hoppenot, President And Chief Executive Officer, Incyte (Photo: Business Wire)

Incyte Corporation (Nasdaq:INCY) announced today that Hervé Hoppenot, former President of Novartis Oncology, has been named President and Chief Executive Officer of Incyte, effective immediately. Mr. Hoppenot, who also will join the Incyte Board of Directors, succeeds Paul A. Friedman, M.D. Dr. Friedman is retiring and will continue to serve on the Board.
Herve Hoppenot, President and Chief Executive Officer, Incyte (Photo: Business Wire)

Herve Hoppenot, President and Chief Executive Officer, Incyte (Photo: Business Wire)

“Hervé’s broad international oncology experience and proven track record in leading successful, high-performing R&D and commercial teams will be of great value as we continue to build upon Incyte’s remarkable success,” said Richard De Schutter, Chairman of the Incyte Board of Directors. “At the time we welcome Hervé to the Incyte team, we especially want to thank and recognize Dr. Friedman for his extraordinary leadership of the company during his tenure as CEO. It is his leadership, together with the quality of the team he assembled, that has enabled Incyte to become the successful biopharmaceutical company it is today.”

As President of Novartis Oncology, Mr. Hoppenot, 53, was responsible for translational medicine, development, approval and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8,000 employees in 50 countries. Prior to his role as President, Mr. Hoppenot served as Chief Commercial Officer and Head of Global Product Strategy & Scientific Development, overseeing medical affairs, global brand leadership, business development and licensing, health economics & pricing, early phase commercial development, strategic capabilities and global sales excellence for Oncology. He joined Novartis in 2003 as Senior Vice President, Head of Global Marketing and has more than twenty-five years of international experience.

Mr. Hoppenot started his career in France with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. He holds a Diploma from ESSEC International Business School.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,890.83 +170.91 0.96%
S&P 500 2,094.40 +13.99 0.67%
NASDAQ 5,134.48 +25.8140 0.51%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs